Cargando…

ChAdOx1 n-COV 19 Vaccine Protected Health Care Workers From Severe Infection Caused by the Variants

Detalles Bibliográficos
Autores principales:	Vaishya, Raju, Malani, Arpita, Mendiratta, Leena, Butta, Hena, Sibal, Anupam, Singh, Sujeet Kumar, K, Hari Prasad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mayo Foundation for Medical Education and Research 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406022/ https://www.ncbi.nlm.nih.gov/pubmed/34479735 http://dx.doi.org/10.1016/j.mayocp.2021.07.016

Ejemplares similares

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
por: Vaishya, Raju, et al.
Publicado: (2021)

SARS-CoV-2 infection after COVID-19 immunization in healthcare workers: A retrospective, pilot study
por: Vaishya, Raju, et al.
Publicado: (2021)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

Inflammatory myositis after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Bifidobacterium: An Emerging Clinically Significant Metronidazole-resistant Anaerobe of Mixed Pyogenic Infections
por: Butta, Hena, et al.
Publicado: (2017)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
por: Hermosilla, Eduardo, et al.
Publicado: (2022)

Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers– A multicenter cohort study
por: Vaishya, Raju, et al.
Publicado: (2021)

Time to Detection of Yeast Isolates in Pediatric and Adult Patients with Fungemia and its Relevance to Clinical Profile and Outcome
por: Butta, Hena, et al.
Publicado: (2019)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

The COVID‐19 vaccine ChAdOx1‐S is not contaminated with sulfated glycosaminoglycans
por: Alban, Susanne, et al.
Publicado: (2022)

Prolonged febrile illness following first dose of ChAdOx1
por: Caruana Dingli, Michael, et al.
Publicado: (2023)

Lack of vaccination and associated comorbidities predispose to the need for intensive care in individuals infected with the delta variant – A case cohort study from a tertiary care hospital in New Delhi, India
por: Vaishya, Raju, et al.
Publicado: (2021)

Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
por: Shetty, Arusha, et al.
Publicado: (2022)

Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
por: Kirsebom, Freja Cordelia Møller, et al.
Publicado: (2022)

Depression following ChAdOx1-S/nCoV-19 vaccine
por: Uvais, N.A.
Publicado: (2022)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination
por: Suan, Dan, et al.
Publicado: (2022)

Myelin Oligodendrocyte Glycoprotein-Associated Disorders Post-ChAdOx1 Vaccination
por: Maramattom, Boby Varkey
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Delayed large local reaction to the adenovirus-vectored (ChAdOx1) vaccine
por: Grobusch, Martin P., et al.
Publicado: (2021)

Central nervous system adverse events after ChAdOx1 vaccination
por: Maramattom, Boby Varkey, et al.
Publicado: (2022)

De novo psoriasis induced by ChAdOx1-S COVID 19 vaccine()
por: Zaiem, Ahmed, et al.
Publicado: (2022)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
por: de Laat, Bas, et al.
Publicado: (2022)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
por: Holm, Sverre, et al.
Publicado: (2021)

Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
por: Hyun, Hakjun, et al.
Publicado: (2021)

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
por: Öcal, Osman, et al.
Publicado: (2021)

Autoimmune encephalitis following ChAdOx1-S SARS-CoV-2 vaccination
por: Kwon, Hyeryung, et al.
Publicado: (2021)

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination
por: Spataro, Rossella, et al.
Publicado: (2022)

Two flares of Still’s disease after two doses of the ChAdOx1 vaccine
por: Roongta, Rashmi, et al.
Publicado: (2022)

ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
por: Baker, Alexander T., et al.
Publicado: (2021)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
por: Berlot, Giorgio, et al.
Publicado: (2022)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
por: Garibashvili, Tamara, et al.
Publicado: (2022)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
por: Krutzke, Lea, et al.
Publicado: (2022)

Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study
por: Chaiwong, Warawut, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago
por: Gopaul, Chavin D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_elmqlpo5th3mej6otgesqi59s9